From 1996 to 2000, several African countries accelerated measles control by providing a second opportunity for measles vaccine through supplemental campaigns. Fifteen countries completed campaigns in children aged 9 months to 14 years. Seven countries completed campaigns in children aged 9-59 months. In almost all countries that conducted campaigns in children aged 9 months to 14 years, measles deaths were reduced to near zero. In six countries, near-zero measles mortality has been maintained for 4-6 years. Supplemental immunization in children !5 years old was only partially effective (range, 0-67%) in reducing mortality. Measles cases decreased by 50% when routine vaccination coverage increased from 50% to 80%. Initial measles campaigns in children aged 9 months to 14 years, follow-up campaigns in those aged 9-59 months every 3-5 years, and increased routine coverage to 80% will be needed to reduce and maintain measles deaths in African countries at near zero.
and presumably measles deaths, did not decline substantially during the 1990s.
In 1996, the polio eradication initiative had its first series of large-scale mass oral poliovirus campaigns in African countries [2] . As the polio eradication initiative became increasingly successful in eliminating wild poliovirus, African countries became more interested in accelerating the control of their number one vaccinepreventable disease priority-measles. In 1998, the WHO African Region Office drafted a regional measles control plan with a target of near-zero measles mortality for most countries.
Here we describe three different measles control approaches used in Africa in recent years and discuss their impact in relation to the regional goal of near-zero measles deaths in most countries. The first approach was an initial campaign in children aged 9 months to 14 years plus follow-up campaigns every 3-4 years in children aged 9 months to 47-59 months. The second approach was measles campaigns in children 9-59 months old (hereafter termed !5 year olds). The third approach was to increase routine measles vaccination coverage from 50% to about 80%.
METHODS

Strategies.
For approach 1, we describe two groups of countries that conducted mass campaigns in !15 year olds with follow-up campaigns every 3-4 years: seven countries in southern Africa (Namibia, Botswana, South Africa, Zimbabwe, Malawi, Swaziland, and Lesotho) in 1996-2000 [3] and eight west, central, and eastern African countries in 2001 and 2002 (Mali, Burkina Faso, Ghana, Togo, Benin, Cameroon, Tanzania, and Kenya). The seven southern Africa countries aimed to eliminate measles [3] , while the other eight countries sought near-zero measles deaths.
For approach 2, we show information from seven countries that conducted campaigns in !5 year olds with routine coverage of 40%-80% (Zambia, Cameroon, Burkina Faso, Mali, Uganda, Mozambique, and Tanzania). For approach 3, we describe three countries where routine immunization increased from about 50% to 80% over several years (Ghana, Cote D'Ivoire, and Mozambique). These countries did not conduct supplemental measles campaigns during the time routine coverage was increasing.
Trends in measles cases and deaths. In general, we used the trends in measles cases and deaths in the 3-5 years before the mass campaign and for 1-2 years after the campaign to evaluate the impact. We used several methods to examine trends in cases and deaths and obtained data by district by month and year from routine surveillance systems in all countries. In addition, we collected data from retrospective record reviews of inpatient and outpatient registers in provincial hospitals, usually over a 5-year period and used line-listing (age and vaccination status) of routinely reported measles cases (Zambia). We also used case-based measles surveillance with laboratory testing from campaigns targeting children !15 years old. The quality of the case-based measles surveillance in the seven southern Africa !15-year-old campaign countries was good [3] . For Uganda and Tanzania, we used line-listed data from sentinel sites on measles cases and deaths (age and vaccination status). Except where references are shown, data are from unpublished surveillance data reports and hospital record reviews written by Ministries of Health (MOH) and WHO country immunization officers or consultants.
Measles deaths averted. To estimate the number of deaths averted, we first estimated the number of measles deaths before the campaign. We based our estimate on 1998 WHO (Geneva) calculations for all countries worldwide to assess the progress that countries had made in reaching the World Summit for Children and World Health Assembly goals of a 95% reduction in measles deaths and a 90% reduction in measles cases compared with preimmunization estimates.
The WHO African Regional Office updated 1995 WHO (Geneva) spreadsheet data with 1998 population and 1999 measles vaccine coverage data [4] . In brief, to calculate measles-related deaths, we multiplied the estimated number of surviving infants in 1998 not protected by measles vaccine (by using routine measles vaccination coverage and a measles vaccine efficacy rate of 85%) by the estimated national average case-fatality rate. This method assumes that all children vaccinated are not infected with measles virus prior to vaccination and that all children not immune from vaccination are infected with measles virus. The case-fatality rate used for most countries in west and central Africa was 4%-6%. Countries with high routine measles coverage (e.g., Malawi) or high economic status (South Africa) were assigned lower case-fatality rates (р1%-2%).
To calculate the number of deaths averted, we used the percentage decline in cases and deaths for each country from table 1 (!5-year-old campaign countries), 100% for southern African countries [3] , and values from [11] and unpublished MOH surveillance data for campaigns for children !15 years old in Burkina Faso, Mali, Benin, Ghana, Togo, and Cameroon in December 2001. The duration of effectiveness used was 3 years for campaigns that targeted children !15 years old (in countries with !80% routine coverage), 1.5 years for campaigns that targeted children !5 years in Mali and Uganda, and 2 years for campaigns aimed at children !5 years old in Burkina Faso and Tanzania (see Results section).
Cost per death averted. To estimate the cost per death averted, we used the total external (donor) funds provided to each country for the campaigns (vaccine, needles, syringes, operational costs). We did not include salary, national MOH financial support, in-country contributions, or in-kind contributions. !15 years old with follow-up campaigns every 3-4 years. In the seven southern African elimination countries, routine vaccination coverage in all countries was about 80% [4] . Adequate measles case-based surveillance with laboratory testing (laboratory specimens collected for all reported suspected cases) was in place in most countries during 1999-2002. In 1999, there were four reported measles deaths after the campaigns; in both 2000 and 2001 there were no reported measles deaths [3] . !5 years old in countries with routine 40%-80% coverage. The second approach to accelerated measles control was tried from 1998 to 2001. Measles supplemental immunizations in children !5 years old were conducted and adequately evaluated in seven countries: Mali [7] , Burkina Faso [5, 6] , Tanzania (unpublished WHO consultant report, 2000), Zambia ( [10] and unpublished Zambia MOH-WHO report), Mozambique [8] , Uganda [9] , and Cameroon (unpublished WHO Cameroon Office Report, 2001). In Mali, children !5 years old in provincial and district capital towns were immunized during supplemental activities in 1998 and in provincial, district, and subdistrict capitals in 1999. In Burkina Faso, 9 cities had supplemental activities in 1998, followed by a nationwide campaign in 1999. In Tanzania, one-third of districts had a campaign in 1999 and a second third of districts had campaigns in 2000. In Uganda, one-third of districts were covered each year from 1999 to 2001. In Zambia, 4 urban cities had campaigns that targeted !5 year olds in 1999 and one-third of districts had similar campaigns in 2000. In Mozambique, 11 provincial capitals had campaigns, and in Cameroon, campaigns of !5 year olds were conducted in 14 cities in the north.
RESULTS
Approach 1: mass campaigns for those
The impact of campaigns in !5 year olds was measured in most countries by calculating the percentage decline in hospital deaths and cases compared with data for 3-5 years before the campaign and for 1-2 years after the campaign. The urban campaigns in Zambia, Mozambique, and Cameroon had no measurable effect. In countries that vaccinated one-third to one-half of children !5 years old (Tanzania, Mali, Burkina Faso, Zambia), declines ranged from 16% after the second, larger campaign in children !5 yeas in 1999 in Mali to 33% in Tanzania to 67% in Uganda. The percentage decline in cases was not related to routine vaccination coverage before the campaign.
Three countries had information on duration of effect of campaigns in children !5 years old. In Burkina Faso the effect was maintained in the second year (in fact, there was slightly more effectiveness in the second year than in the first year; [5] , unpublished Burkina Faso MOH-WHO data). In Mali, cases were reduced by an estimated 16% in the second year compared with 53% in the first year ( [12] , unpublished Mali MOH-WHO report). In Uganda, the effect lasted 15-22 months until cases increased to pre-campaign levels [9] .
Approach 3: increasing routine immunization coverage from ∼50% to 80% over several years. Figure 1 shows trends in measles cases and routine measles immunization coverage from 1981 to 2000 for Ghana, Cote D'Ivoire, and Mozambique. On average, there was about a 50% decline (range, 41%-53%) in reported measles cases when routine immunization increased from 50% in the early or mid-1990s to 73%-90% in 1999. In Ghana, a mean of 33,513 measles cases occurred during 1991-1996, when routine coverage was 40%-53%, and 19,687 (a decline of 41%) during 1997-2000, when routine coverage increased from 59% in 1997 to 84% in 2000. In Cote d'Ivoire, a mean of 16,606 measles cases occurred during 1991-1996, when routine coverage was 41%-56%, but just 7859 (a decline of 53%) during 1997-2000, when routine coverage was 57%-73%. In Mozambique, a mean of 15,093 measles cases was reported for 1981-1990, when routine measles vaccine coverage was 32%-59%, and 7931 cases during 1991-2000 (a decline of 47%), when routine coverage increased from 55% in 1991 to 87%-97% in 1998-2000. In Ghana, Mozambique, and Table 2 and table 3 , respectively, show the age distribution of deaths and cases. In most countries (even those with routine measles vaccine coverage of 50%: Mali, Burkina Faso, Togo, Cameroon), there was an epidemiologic transition to significant percentages of measles cases in older age groups. In several countries, у10%-15% of cases occurred in persons у15 years old (table 3) . Data in table 3 show that for four of six locations (Mali, Burkina Faso, Cameroon, rural Zambia) about 30%-50% (except for 12% in urban Lusaka, Zambia, and 7% in Uganda) of measles deaths occurred in children у5 years old, even before supplemental mass campaigns in countries with 50% routine coverage (Mali, Burkina Faso, Cameroon). In Zambia, Burkina Faso, and Uganda (table 4), the case-fatality rates in older children (у5 years) were lower than in children !5 years, but remained one-half to one-third of the case-fatality rates of children !5 years old. In Burkina Faso, the case-fatality rate for persons 115 years old was just half that of children !5 years old (3% and 6%, respectively) for several years (1994) (1995) (1996) (1997) 
DISCUSSION
Our primary conclusion was that only campaigns that targeted children !15 years old with follow-up led to mortality reductions consistent with the regional target of near-zero measles deaths. To maintain measles deaths near zero, the campaign strategy for persons !15 years old must be combined with routine measles vaccination coverage у80% and there must be follow-up campaigns in children aged !4 to 5 years every 3-4 years. Measles deaths did not reach (nor were maintained at) near zero after campaigns targeting those !5 years old or after routine coverage of 80% alone.
Our findings have several limitations. Because our observations were uncontrolled, we could not account for or control for different factors among the different approaches. The postcampaign observations from countries that conducted measles vaccination campaigns for children !5 years old were available for !3 years in most countries. The duration of post-campaign observations was limited because most countries with campaigns that targeted children !5 years conducted a second campaign in children !15 years old. In estimating the numbers of measles deaths in 1998 prior to the campaigns, our estimate of the average case-fatality rates may be too high in some coun- tries. We did not account for population growth or for children being infected with measles prior to vaccination (many children are vaccinated substantially after age 9 months). Because measles is cyclical, the impact of the campaigns in children !5 years old may be under-or overestimated depending on the timing of the campaigns and the cycle of measles outbreaks. The age distribution of cases was primarily from health facility data and not population based. However, age distributions by population density and measles vaccine coverage were remarkably consistent across countries (table 3) . In addition, health facility cases are likely to be more severe, which is of more interest for a mortality reduction strategy. The ages of cases (table 2) and deaths (table 3) suggest why campaigns in children !5 years old had a low impact (table 1) . The epidemiologic factors responsible for decreased effectiveness of these campaigns are that there are more cases in children у5 years old than previously thought, case-fatality rates in older children are higher than previously thought, measles virus infection in children у5 years is a reservoir and source of infections in younger children, and therefore many nonimmune children (those born since last campaign, missed by routine immunization and supplemental campaigns, and nonimmune despite vaccinations) and children infected prior to routine vaccination after the campaign are not being protected.
Although we could not account for all factors, the effect of the age group (!15 vs. !5 years) was consistent across several factors. Campaign coverage was 180% in all campaigns. The campaigns that targeted persons !15 years old had the same effectiveness whether they were subnational, national, or split over 2 years. Campaigns targeting children !5 years old had the same effectiveness whether they were subnational, national, or split over 2-3 years. Both approaches were used by countries with relatively low and relatively high routine coverage.
Data show that limited and urban campaigns had a very low impact (table 1) . For most countries, the !15-year-old age group is the appropriate group for an initial mass campaign, even in low-coverage countries (40%-60%) with low population density and for any country with age shift of measles cases to older age groups. A campaign targeting children aged !10 years might only be considered in countries with very low by guest on July 28, 2015 http://jid.oxfordjournals.org/ routine coverage (30%-50%), a moderately high population density (1100 persons/km 2 ), and where 190% of reported measles cases are !10 years old.
The results for campaigns for children !15 years and !5 year old were consistent with other data. The campaign for children !15 and follow-up strategy in southern Africa provided the same dramatic decline in mortality and morbidity as in the Americas [13, 14] . Limited age group mass campaigns conducted in Africa in the 1960s that were associated with smallpox campaigns and at other times also showed limited duration of effectiveness [15] [16] [17] [18] .
Most countries that have conducted measles campaigns in persons !15 years old achieved routine coverage of about 80% (7 southern African countries plus Benin, Ghana, Tanzania, and Kenya). However, four countries (Mali, Burkina Faso, Togo, Cameroon) initiated supplemental immunizations when routine measles vaccination coverage was about 50%. It is expected that these four countries will reach 80% coverage by 2005, the target set by the Global Alliance for Vaccines and Immunizations (GAVI). There is evidence from routine immunization reporting to WHO from Mali and Burkina Faso that routine coverage increased in the last 12-18 months. Fortunately, momentum is building from three directions to increase routine coverage to 80% in most African countries by 2005-the polio eradication initiative (to prevent circulating vaccine-derived poliovirus from emerging [19] ), the measles initiative (to maintain measles deaths near zero), and GAVI (increased routine immunization infrastructure and introduction of more expensive new vaccines: hepatitis B and Haemophilus influenza type B). A remaining question is the role of supplemental immunization in countries with very weak immunization infrastructure (routine measles coverage !50%) that is not significantly increasing. Funds may be more profitably put into routine immunization in those countries.
The $122 cost per death averted makes measles vaccination campaigns in persons !15 years old and follow-up secondopportunity supplemental campaigns cost-effective public health interventions. No other public health interventions available to African countries can reduce a top-five cause of child mortality to a sustainable level of near-zero deaths at such a low cost. The child mortality rate in Africa remains nearly twice that of other regions [20] and urgent action is needed to accelerate the decline of child mortality. Although 170,000 measles deaths were averted in the last 5 years by the activities described, nearly 2.5 million African children died of measles since these activities started in 1996. Funding shortages were critical factors for conducting partially effective campaigns in children !5 years old instead of targeting children !15 years old. It is puzzling why countries and partner agencies have not been more aggressive in applying this intervention to dramatically reduce child deaths in Africa. At $0.14 per dose of measles vaccine, we may never again see a more cost-effective public health intervention.
